Clinical trial for MS patients
Granalix is planning a clinical trial for MS patients in which GranaGard will be administered in addition to conventional drugs.
Mechanism of action
Preliminary experiments have shown that GranaGard can modulate the activity of mitochondrial enzymes, resulting in reduction of reactive species production thereby reducing the toxicity of respiration to cells.
Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and is associated with demyelination, neurodegeneration, and sensitivity to oxidative stress. In this work, we administered a nanodroplet formulation of pomegranate seed oil (PSO), denominated Nano-PSO, to mice induced for experimental autoimmune encephalomyelitis (EAE), an established...
Pomegranate seed oil nanoemulsions for the prevention and treatment ofneurodegenerative diseases: the case of genetic CJD
Neurodegenerative diseases generate the accumulation of specific misfolded proteins, such as PrPSc prions or A-beta in Alzheimer’s diseases, and share common pathological features, like neuronal death and oxidative damage. To test whether reduced oxidation alters disease manifestation, we treated TgMHu2ME199K mice, modeling for genetic prion disease, with Nano-PSO, a...
